

Ⅲ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表レイアウト

書籍（日本語）

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
古川洋一	「変異」（チャプター）	日本人類遺伝学会	コアカリ準拠臨床遺伝学テキストノート	診断と治療社	東京	2018	14-16
古川洋一	「DNA損傷と修復」（チャプター）	日本人類遺伝学会	コアカリ準拠臨床遺伝学テキストノート	診断と治療社	東京	2018	17-19
古川 洋一	「次世代シーケンス解析技術の進歩とその臨床応用」	松本直通、難波栄二、古川洋一	遺伝子医学 MO OK34号 臨床応用に向けた疾患シーケンス解析	メディカル・ドゥ	大阪	2018	27-31
佐治重衡	乳癌診療ガイドライン 2018年版	日本乳癌学会	乳癌診療ガイドライン	金原出版		2018	-
加藤雅志	がん・生殖医療ハンドブック	大須賀穰、鈴木直	短時間のうちに多くの意思決定を迫られる患者にどう関わる？—がん相談支援センターがん専門相談員の立場から。	メディカ出版	大阪	2017	313-318
加藤雅志	緩和ケアと精神保健 第6版精神保健福祉士養成セミナー第2巻 精神保健学	加藤雅志	精神保健の課題と支援.	へるす出版	東京	2017	164-179

雑誌 (外国語)

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tamura K, Kodaira M, Shimizu C et al.	Phase I study of taselelisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.	Cancer Sci.	109	1592-1601	2018
Yonemori K, Kodaira M, Satoh T, Tamura K et al.	A phase I study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.	Cancer Sci	-	Epub ahead of print	2018
Inagaki C, Shimoi T, Okuma H, Tamura K et al.	A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. Anticancer Drugs. 10.1097/CAD.0000000000000558,	Anticancer Drugs.	-	Epub ahead of print	2018
Sawada T, Hilhorst R, Rangarajan S, Tamura K et al.	Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles.	Oncotarget	28	34229-34239	2018
Shimoi T, Hamada A, Yamagishi M, Tamura K et al.	PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.	Cancer Sci	109	2558-2566	2018
Iwasa S, Yamamoto N, Shitara K, Tamura K et al.	Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.	Cancer Sci.	109	3216-3223	2018
Tanaka R, Yonemori K, Hirakawa A, Tamura K et al.	Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data.	Oncologist	-	Epub ahead of print	2018
Iizumi S, Shimomura A, Shimoi T, Tamura K et al.	Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.	Cancer Chemother Pharmacol.	-	Epub ahead of print	2018
Cortes J, Tamura K, DeAngelo DJ. et al.	Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer.	Br J Cancer	118	1425-1433	2018

Noguchi E, <u>Tamura K</u> , Hattori M. et al.	Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study. Breast Cancer.	Breast	-	Epub ahead of print	2018
Ebata T, Shimoi T, Bun S, <u>Tamura K</u> . et al.	Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor. Oncology.	Oncology.	94	340-344	2018
<u>Furukawa Y.</u>	Implementation of genomic medicine for gastrointestinal tumors.	Annals of Gastroenterological Surgery	2(4)	246-252	2018
Matsuura M, Yamaguchi K, Tamate M, Satohisa S, Teramoto M, Iwasaki M, Sugita S, Hasegawa T, Koubo R, Takane K, Ikenoue T, <u>Furukawa Y</u> , Saito T	Efficacy of liquid-based genetic diagnosis of endometrial cancer	Cancer Science	109(12)	4025-4032	2018
Nakazawa Y, Yamamoto R, <u>Kato M</u> , Miyashita M, Kizawa Y, Morita T.	Improved Knowledge of and Difficulties in Palliative care among physicians during 2008 and 2015 in Japan: association With a nationwide palliative care education program.	Cancer.	-	Epub ahead of print	2017
Nakazawa Y, <u>Kato M</u> , Miyashita M, et al	Changes in nurses' knowledge, difficulties, and self-reported practices toward palliative care for cancer patients in Japan: an analysis of two nationwide representative surveys in 2008 and 2015.	J Pain Symptom Manage.	-	Epub ahead of print	2017
Miyoshi Y, Yorifuji T, Horikawa R, Takahashi I, Nagasaki K, Ishiguro H, Fujiwara I, Ito J, Oba M, Fujisaki H, <u>Kato M</u> , Shimizu C, Kato T, Matsumoto K, Sago H, Takimoto T, Okada H, Suzuki N, Yokoya S, Ogata T, Ozono K.	Childbirth and fertility preservation in childhood and adolescent cancer patients: a second national survey of Japanese pediatric endocrinologists.	Clin Pediatr Endocrinol	26(2)	81-88,	2017

Nakazawa, Y., <u>Kato, M.</u> , Yoshida, S., Miyashita, M., Morita, T., & Kizawa, Y.	Population-based quality indicators for palliative care programs for cancer patients in Japan: A delphi study.	Journal of Pain and Symptom Management,	51(4)	652-661	2017
Wang R, Yamada T, Arai S, Fukuda K, Taniguchi H, Tanimoto A, Nishiyama A, Takeuchi S, Yamashita K, Ohtsubo K, Matsui J, Onoda N, Hirata E, Taira S, <u>Yano S.</u>	Distribution and activity of lenvatinib in brain tumor models of human anaplastic thyroid cancer cells in severe combined immune deficient mice.	Mol Cancer Ther	18(5)	947-956	2019
Fukuda K, Takeuchi S, Arai S, Katayama R, Nanjo S, Tanimoto A, Nishiyama A, Nakagawa T, Taniguchi H, Suzuki T, Yamada T, Nishihara H, Ninomiya H, Ishikawa	Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status.	Cancer Res	79(7)	1658-1670	2019
Taniguchi H, Yamada T, Wang R, Tanimura K, Adachi Y, Nishiyama A, Tanimoto A, Takeuchi S, AL, Boroni M, Yoshimura A, Shiotsu S, Matsumoto I, Watanabe S, Kikuchi T, Miura S, Tanaka H, Kitazaki T, Yamaguchi H, Mukae H, Uchino J, Uehara H, Takayama K, <u>Yano S.</u>	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.	Nat Commun	10(1)	259	2019
Tanimoto A, Takeuchi S, Kotani H, Yamashita K, Yamada T, Ohtsubo K, Ebi H, Ikeda H, <u>Yano S.</u>	Pulmonary carcinosarcoma showing an obvious response to pazopanib: a case report.	BMC PulmonaryMedicine	18(1)	193	2018
Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, <u>Yano S.</u>	Foretinib overcomes entrectinib resistance associated with the <i>NTRK1</i> G667C mutation in <i>NTRK1</i> fusion-positive tumor cells in a brain metastasis model.	Clin Cancer Res	24	2357-2369	2018
Kotani H, Adachi Y, Kitai H, Tomida S, Bando H, Faber AC, Yoshino T, Voon DC, <u>Yano S.</u> , Ebi H.	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.	Oncogene	37	1775-1787	2018
akashita A, Kizawa Y, Kato M, Akizuki N, Nakazawa Y, Kaizu M, Yano K, Sato T, Tokoro A.	Development of a Standard for Hospital-Based Palliative Care Consultation Team in Japan Using a Modified Delphi Method.	Journal of Painand Symptom Management,	56(5)	746-751	2018
Yoshida S, Ogawa C, Shimizu K, Kobayashi M, Inoguchi H, Oshima Y, Dotani C, Nakahara R, <u>Kato M.</u>	Japanese physicians' attitudes toward end-of-life discussion with pediatric patients with cancer.	Supportive Care in Cancer,	26(11)	3861-3871.	2018
Takeuchi E, <u>Kato M.</u> , Miyata K, Suzuki N, Shimizu C, Okada H, Matsunaga N, Shimizu M, Moroi N, Fujisawa D, Mimura M, Miyoshi Y.	The effects of an educational program for non-physician health care providers regarding fertility preservation.	Supportive Care in Cancer,	26(10)	3447-3452.	2018

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Tamura K, Imamura CK, Takano T, et al.	<i>CYP2D6</i> Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase	J Clin Oncol	38	558-566	2020
Modi S, Saura C, Yamashita T, Tamura K et al.	DESTINY-Breast01 Investigators: Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast	N Engl J Med.	382	610-621	2020
Ebata T, Yonemori K, Nishikawa T, Tamura K et al.	Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.	Oncology	98	699-705	2020
Noda-Narita S, Shimomura A, Tanabe Y, Tamura K et al.	Peripheral Neuropathy From Paclitaxel: Risk Prediction by Serum microRNAs	BMJ Support Palliat Care		doi: 10.1136/bmjspcare-2019-001900-2020	2020
Uehara T, Yoshida H, Fukuhara M, Tamura K et al.	Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients	Gynecol Oncol.	157	398-404	2020
Modi S, Park H, Murthy RK, Tamura K et al.	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.	J Clin Oncol	38	1887-1896	2020
Iwata H, Inoue K, Kaneko K, Tamura K et al.	Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)	Jpn J Clin Oncol.	50	223. doi: 10.1093/jjco/hyz208, 2020	2020
Yoshida A, Arai Y, Hama N, Tamura K et al.	Expanding the clinicopathologic and molecular spectrum of BCOR-associated sarcomas in adults.	Histopathology	76	Epub ahead of print	2020
Kato MK, Yunokawa M, Bun S, Tamura K, et al.	Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data	J Cancer Res Clin Oncol	146	1335-1341	2020
Seo T, Noguchi E, Yoshida M, Tamura K et al.	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation	Case Rep Oncol Med	6	2518383. doi: 10.1155/2020/2518383. eCollection,	2020
Matsumoto K, Takahashi M, Sato K, Tamura K. et al.	A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide.	Cancer Med	9	3319-3327	2020

Tsurutani J, Iwata H, Krop I, <u>Tamura K.</u> et al.	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors	Cancer Discov.	10	688-701	2020
Watanabe S, Shimomura A, Kubo T, <u>Tamura K.</u> et al.	BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.	Mod Pathol.	33	1660-1668	2020
Sugano T, Yoshida M, Masuda M, <u>Tamura K.</u> et al.	Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma.	Br J Cancer.	122	1811-1817	2020
Tanabe Y, Shiraishi S, Hashimoto K, <u>Tamura K.</u> et al.	Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients. BMC Cancer.	BMC Cancer.	20	325. doi: 10.1186/s12885-020-06834-0., 2020	2020
Smyth LM, <u>Tamura K.</u> , Oliveira M, et al	Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with <i>AKT1</i> ^{E17K} -Mutant, ER-Positive Metastatic Breast Cancer.	Clin Cancer Res	26	3947-3957	2020
Kawachi A, Yamashita S, Okochi-Takada E, <u>Tamura K.</u> et al	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy	Breast Cancer Res Treat	181	323-329	2020
Mehnert JM, Bergsland E, O'Neil BH, <u>Tamura K.</u> et al	Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Cancer	Cancer	126	3021-3030	2020
Sanchez Calle A, Yamamoto T, Kawamura Y, <u>Tamura K.</u> et al	Long non-coding NR2F1-AS1 is associated with tumor recurrence in estrogen receptor-positive breast cancers	Mol Oncol.	14	2271-2287	2020
Mizuno T, Kojima Y, Yonemori K, <u>Tamura K.</u> et al	HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenocarcinoma of the cervix	Oncol Lett.	20	38. doi: 10.3892/ol.2020.11899. Epub	2020
Hayashi N, Kumamaru H, Isozumi U, <u>Tamura K.</u> et al	Annual report of the Japanese Breast Cancer Registry for 2017 Breast Cancer.	Breast cancer	27	803-809	2020
Minami H, Ando Y, <u>Tamura K.</u> et al	Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer	Anticancer Res	40	5229-5235	2020

Watanuki R, Shimomura A, Yazaki S, <u>Tamura K.</u> et al	Survival outcomes in patients with human epidermal growth factor receptor 2 positive metastatic breast cancer administered a therapy following trastuz	Medicine (Baltimore).	18	99(38):e22331. doi: 10.1097/MD.00000000022331	2020
Ryu S, Ohuchi M, Yagishita S, <u>Tamura K.</u> et al	Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spect	Sci Rep.	23	10(1):15535. doi: 10.1038/s41598-020-72665-5	2020
Mizuno T, Kojima Y, Yonemori K, <u>Tamura K.</u> et al	Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer	Oncol Lett	20	336. doi: 10.3892/ol.2020.12200. Epub	2020
Kondo S, Shimizu T, Koyama T, <u>Tamura K.</u> et al	First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors	Cancer Sci	7	doi: 10.1111/cas.14765. Online ahead of print	2020
Hata T, Nakamura K, Yonemori K, <u>Tamura K.</u> et al	Regulatory and Operational Challenges in Conducting Asian International Academic Trial for Expanding the Indications of Cancer Drugs	Clin Transl Sci	-	doi: 10.1111/cts.12965. Online ahead of print,	2020
Yamamoto N, Shimizu T, Yonemori K, <u>Tamura K.</u> et al	A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors	Invest New Drugs	9	doi: 10.1007/s10637-020-01055-5. Online ahead of print	2020

雑誌（日本語）

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
<u>川上尚人</u>	希少フラクションを標的とした切除不能・進行再発大腸がんの臨床開発	腫瘍内科	22 (1)	17-23	2018
秋月晶子, 秋月伸哉, 中澤葉字子, 安保博文, 伊勢雄也, 岡本禎晃, 海津美希子, 品田雄市, 山代亜紀子, 坂下明大, <u>加藤雅志</u> .	緩和ケアチームセルフチェックプログラムの実施可能性に関する多施設調査.	Palliative Care Research	13(2)	195-200	2018
<u>加藤雅志</u> .	国の動向と担当者として考えていたこと 国の施策と行政の立場からの関わり. ホスピス緩和ケア白書2018.	青海社	-	2-5	2018
<u>加藤雅志</u> .	がん・生殖医療ハンドブック 大須賀 穰 鈴木 直 編集 短時間のうちに多くの意思決定を迫られる患者にどう関わる?—がん相談支援センターがん専門相談員の立場から.	メディカ出版	-	313-318	2017
<u>加藤雅志</u> .	緩和ケアと精神保健. 第6版精神保健福祉士養成セミナー第2巻 精神保健学 - 精神保健の課題と支援.	へるす出版,	-	164-179,	2017
<u>加藤雅志</u> .	緩和ケアとがん対策基本法	精神科	31(4)	275-280	2017
<u>加藤雅志</u> .	がん診療の地域医療連携の現状—積極的に参加しよう—	Medical Practice	34	24-29	2017
<u>加藤雅志</u> .	緩和ケアの魔法の言葉. 森田達也 責任編集 緩和ケア2016年6月増刊号	青海社	-	87-90	2016
<u>加藤雅志</u> .	総合病院での緩和ケアチーム. 山本賢司 編著 精神科領域のチーム医療実践マニュアル	新興医学出版社	-	97-113	2016